Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.

In vivo (Athens, Greece) - 1 Jan 2000

Kim So-Woon, Park Bong Jin, Kim Hyun-Soo, Na Kiyong

Abstract excerpt

BACKGROUND/AIM: The application of Oncomine Comprehensive Assay v3 (OCAv3) panel in diffuse gliomas (DGs) remains unknown. We investigated the utility of OCAv3-based next-generation sequencing (NGS) in isocitrate dehydrogenase (IDH)-mutated grade II-III DGs. PATIENTS AND METHODS: We collected 20 tissue samples obtained from IDH-mutated grade II-III DG patients and performed OCAv3-based NGS. RESULTS: By...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 1

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Oligodendroglioma

Source

Open in PubMed Open full text

Identifiers

PMID: 33622884
DOI: 10.21873/invivo.12332
PMCID: PMC8045052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.PMID 33622884Read ↗

Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors.Semantic proximity Read ↗

Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.Semantic proximity Read ↗

miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targetsSemantic proximity Read ↗

Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.Semantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear PreparationsSemantic proximity Read ↗

Design and Validation of a Gene-Targeted, Next-Generation Sequencing Panel for Routine Diagnosis in GliomasSemantic proximity Read ↗

Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.Semantic proximity Read ↗

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.Semantic proximity Read ↗

Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.Semantic proximity Read ↗

Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment.Semantic proximity Read ↗

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.